Clinical Trial Detail

Clinical Trials

Clinical Trial Detail

A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors

Complete title: A phase 1, multicenter, open-label, dose-escalation study of SGN-2FF in patients with advanced solid tumors

Research Study Number 20162576
Principal Investigator Laura Chow
Phase I

Research Study Description

This study will examine the safety profile of SGN-2FF. The study will test increasing doses of SGN-2FF given daily to small groups of patients.

Eligibility Criteria (must meet the following to participate in this study)

** For Eligibility information, please click on the "Look up trial at NIH" link above. **

Other eligibility criteria may apply.

Research Study Number 20162576
Contact Seattle Cancer Care Alliance Intake Office
Telephone 800-804-8824 / 206-606-1024

Keywords: Bladder Cancer; Breast Cancer; Gastrointestinal Cancer; Head and Neck Cancer; Lung Cancer; Renal Cancer; Solid Tumors; Lung Carcinoma, Non-Small-Cell (NSCLC); Carcinoma, Bronchogenic; Urogenital Neoplasms; Urologic Neoplasms; Neoplasms, Glandular and Epithelial; Adenocarcinoma; Colorectal Neoplasms; Neoplasms, Respiratory Tract; Neoplasms, Thoracic; Urinary Bladder Neoplasms; Carcinoma, Renal Cell; Intestinal Diseases; Intestinal Neoplasms

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials